ADMA Biologics, Inc. (ADMA)
NASDAQ: ADMA · Real-Time Price · USD
15.02
+0.15 (1.01%)
At close: Mar 19, 2026, 4:00 PM EDT
15.00
-0.02 (-0.13%)
After-hours: Mar 19, 2026, 6:39 PM EDT
ADMA Biologics Revenue
In the year 2025, ADMA Biologics had annual revenue of $510.17M with 19.63% growth. ADMA Biologics had revenue of $139.16M in the quarter ending December 31, 2025, with 18.39% growth.
Revenue (ttm)
$510.17M
Revenue Growth
+19.63%
P/S Ratio
7.01
Revenue / Employee
$788,521
Employees
647
Market Cap
3.58B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 510.17M | 83.72M | 19.63% |
| Dec 31, 2024 | 426.45M | 168.24M | 65.15% |
| Dec 31, 2023 | 258.22M | 104.14M | 67.59% |
| Dec 31, 2022 | 154.08M | 73.14M | 90.36% |
| Dec 31, 2021 | 80.94M | 38.72M | 91.72% |
| Dec 31, 2020 | 42.22M | 12.87M | 43.85% |
| Dec 31, 2019 | 29.35M | 12.36M | 72.79% |
| Dec 31, 2018 | 16.99M | -5.78M | -25.37% |
| Dec 31, 2017 | 22.76M | 12.10M | 113.49% |
| Dec 31, 2016 | 10.66M | 3.48M | 48.53% |
| Dec 31, 2015 | 7.18M | 1.26M | 21.34% |
| Dec 31, 2014 | 5.92M | 2.85M | 92.84% |
| Dec 31, 2013 | 3.07M | 1.95M | 174.35% |
| Dec 31, 2012 | 1.12M | 357.08K | 46.92% |
| Dec 31, 2011 | 761.04K | - | - |
| Jun 30, 2011 | - | - | - |
| Dec 31, 2010 | - | - | - |
| Jun 30, 2010 | - | - | - |
| Jun 30, 2009 | - | - | - |
| Jun 30, 2008 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| ACADIA Pharmaceuticals | 1.07B |
| Corcept Therapeutics | 761.41M |
| Ligand Pharmaceuticals | 268.09M |
| NewAmsterdam Pharma Company | 22.50M |
| Centessa Pharmaceuticals | 15.00M |
| Crinetics Pharmaceuticals | 7.70M |
| Dianthus Therapeutics | 2.04M |
ADMA News
- 17 days ago - ADMA Biologics Announces $125 Million Accelerated Share Repurchase with JPMorgan as Part of a Planned $200 Million 2026 Total Share Repurchase Initiative - GlobeNewsWire
- 21 days ago - ADMA Biologics, Inc. (ADMA) Q4 2025 Earnings Call Transcript - Seeking Alpha
- 22 days ago - ADMA Biologics Reports Record Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update - GlobeNewsWire
- 4 weeks ago - ADMA Biologics to Report Fourth Quarter and Full Year 2025 Financial Results on February 25, 2026 - GlobeNewsWire
- 2 months ago - ADMA Biologics: Business Update And My Price Target - Seeking Alpha
- 2 months ago - ADMA Biologics, Inc. (ADMA) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript - Seeking Alpha
- 2 months ago - ADMA Biologics Announces Preliminary Full Year 2025 Unaudited Total Revenue and Provides Business Update - GlobeNewsWire
- 2 months ago - ADMA Biologics to Present at the J.P. Morgan Healthcare Conference on January 12, 2026 - GlobeNewsWire